Alex Delbridge

Alex Delbridge PhD is a Senior Investment Associate at Omega Funds, with a comprehensive background in investment and research within the biotechnology and pharmaceutical sectors. Experience includes serving as a Board Observer for several companies, including BridgeBio Oncology Therapeutics, NRG Therapeutics, Scorpion Therapeutics, and previously for Photys Therapeutics. Prior roles encompass consulting at Putnam Associates, delivering commercial strategy guidance to leading pharmaceutical clients, and postdoctoral research at Biogen focused on multiple sclerosis and neuroimmunology. Educational credentials include a PhD in Oncology and Cancer Biology from the University of Melbourne, along with advanced studies in leadership and business readiness from Harvard Business School Online and other degrees from the University of Melbourne in medical biology and pharmacology.